

DAFTAR PUSTAKA

1. UNAIDS. AIDS Data. *Jt United Nations Program HIV/AIDS*. 2016.
2. Kementerian Kesehatan RI. *Profil Kesehatan Indonesia 2015*. (Budijanto D, Yudianto, Hardhana B, Soenardi TA, ed.). Jakarta; 2016. doi:351.077 Ind
3. Donald KA, Hoare J, Eley B, Wilmshurst JM. Neurologic complications of pediatric human immunodeficiency virus: Implications for clinical practice and management challenges in the African setting. *Semin Pediatr Neurol*. 2014;21(1):3–11. doi:10.1016/j.spen.2014.01.004
4. Siddiqi O, Birbeck GL. Safe Treatment of Seizures in the Setting of HIV / AIDS. *Curr Treat Options Neurol*. 2013;15(4):529–543. doi:10.1007/s11940-013-0237-6
5. Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: A global perspective. *Eur J Paediatr Neurol*. 2007;11(1):1–9. doi:10.1016/j.ejpn.2006.10.006
6. Fergusson P, Tomkins A. HIV prevalence and mortality among children undergoing treatment for severe acute malnutrition in sub-Saharan Africa : a systematic review and meta-analysis. *Trans R Soc Trop Med Hyg*. 2009;103(6):541–548. doi:10.1016/j.trstmh.2008.10.029
7. WHO. *WHO child growth standards and the identification of severe acute malnutrition in infants and children.*; 2009.
8. Advisory G, Blood C, Blut A, Assessment S. Human Immunodeficiency Virus (HIV). *Transfus Med Hemotherapy*. 2016;43(3):203–222. doi:10.1159/000445852
9. Reeves JD, Doms RW. Human immunodeficiency virus type 2. *J Gen Virol*. 2002;83:1253–1265.
10. Gigantesco A, Giuliani and M. HIV Virology and Pathogenetic Mechanisms of Infection: a Brief Overview. *Ann Ist Super Sanità*. 2010;47(1):5–14. doi:10.4415/ANN
11. Sims G. *Hiv/Aids*. United Kingdom; 2009. doi:10.1007/SpringerReference_69947
12. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. *Lancet*. 2014;384(9939):258–271. doi:10.1016/S0140-6736(14)60164-1
13. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: Pathogenesis, mechanisms and pathways. *Clin Perinatol*. 2010;37(4):721–737. doi:10.1016/j.clp.2010.08.004
14. Kementerian Kesehatan RI. *Pedoman Penerapan Terapi HIV pada Anak*. Jakarta; 2014.
15. Lodha R, Upadhyay A, Kapoor V, Kabra SK. Clinical Profile and Natural History of

- Children with HIV Infection. *Indian J Pediatr.* 2006;73:201–204.
16. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. *Bull World Health Organ.* 2003;81(00):61–70.
 17. Jayanti K, Wati K, Adnyana I, Suarta I. Faktor-faktor yang memengaruhi status imunisasi pada anak dengan infeksi human immunodeficiency virus. 2016;51:137–144.
 18. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children : Towards Universal Access. 2010.
 19. Pedrini M, Brabin B, Pedrini M, et al. Clinical, nutritional and immunological characteristics of HIV-infected children in an area of high HIV prevalence Clinical , nutritional and immunological characteristics of HIV-infected children in an area of high HIV prevalence. *J Trop Pediatr.* 2015;61(4):286–294. doi:10.1093/tropej/fmv038
 20. Jesson J, Koumakpai S, Diagne NR, et al. Effect of Age at Antiretroviral Therapy Initiation on Catch up Growth within the First 24 momnths among HIV infected Children in the leDEA West African Pediatric Cohort. *Pediatr Infect Dis J.* 2016;34(7):1–21. doi:10.1097/INF.0000000000000734.
 21. Mwiru RS, Spiegelman D, Duggan C, et al. Nutritional Status and Other Baseline Predictors of Mortality among HIV-Infected Children Initiating Antiretroviral Therapy in Tanzania. *J Int Assoc Provid AIDS Care.* 2015;14(2):172–179. doi:10.1177/2325957413500852
 22. Mda S, Raaij JMA Van, Villiers FPR De, Kok FJ. Impact of Multi-Micronutrient Supplementation on Growth and Morbidity of HIV-Infected South African Children. *Nutrients.* 2013;5:4079–4092. doi:10.3390/nu5104079
 23. Gerstner T. Oral valproic acid for epilepsy — Long-term experience in therapy and side effects Oral valproic acid for epilepsy – long-term experience in therapy and side effects. *Expert Opin Pharmacother.* 2017;9(2):1–8. doi:10.1517/14656566.9.2.285
 24. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. *Clin Biochem.* 2013. doi:10.1016/j.clinbiochem.2013.06.012
 25. Idris NS, Grobbee DE, Burgner D, et al. Cardiovascular manifestations of HIV infection in children. *Eur J Prev Cardiol.* 2015;22(11):1452–1461. doi:10.1177/2047487314560086
 26. Cheung M. Cardiac Effects of Antiretroviral-Naïve versus Antiretroviral-Exposed HIV Infection in Children Cardiac Effects of Antiretroviral-Na ĩ ve versus Antiretroviral-Exposed HIV Infection in Children. *PLoS One.* 2016;11(1). doi:10.1371/journal.pone.0146753

27. Jacobson DL, Patel K, Siberry GK, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: Outcomes from the Pediatric HIV/AIDS Cohort Study. *Am J Clin Nutr*. 2011;94(6):1485–1495. doi:10.3945/ajcn.111.020271
28. Nsagha DS, Clement J, Assob N, et al. Risk Factors of Cardiovascular Diseases in HIV / AIDS Patients on HAART. *Open AIDS J*. 2015;9:51–59.
29. Sherr L, Croome N, Parra K, Bradshaw K, Herrero R. Children and Youth Services Review Developmental challenges in HIV infected children — An updated systematic review. *Child Youth Serv Rev*. 2014;45:74–89. doi:10.1016/j.childyouth.2014.03.040
30. Foster C. J, Biggs RL, Melvin D, et al. Neurodevelopmental outcomes in children with HIV infection under 3 years of age. *Dev Med Child Neurol*. 2006;48(8):677–682. doi:10.1017/S0012162206001423
31. Williams PL, Mayondi GK, Chaudhury S, et al. Neurodevelopment of HIV-Exposed and HIV-Unexposed Uninfected Children at 24 Months. *Pediatrics*. 2017;140(4):1–10.
32. Bangirana P, John CC, Idro R, et al. Socioeconomic Predictors of Cognition in Ugandan Children : Implications for Community Interventions. *PLoS One*. 2009;4(11):2–7. doi:10.1371/journal.pone.0007898
33. Mock CM, Schwerscenu KH. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. *Am J Heal Syst Pharm*. 2012;69(1):35–39. doi:10.2146/ajhp110049
34. Atkinson P, Das KB, Aylett SE, et al. Neurobehavioral Comorbidities in Children With Active Epilepsy : A Population-Based Study. *Pediatrics*. 2014;133(6):e1586-93.
35. Baillieu N, Potterton J. The Extent of Delay of Language , Motor , and Cognitive Development in HIV-Positive Infants. *J Neurol Phys Ther*. 2008;32(3):118–121. doi:10.1097/NPT.0b013e3181846232
36. Dinaj-koci V, Chen X, Deveau L, et al. Developmental Implications of HIV Prevention During Adolescence : Examination of the Long-Term Impact of HIV Prevention Interventions Delivered in Randomized Controlled Trials in Grade Six and in Grade 10. *Youth Soc*. 2015;47(2):151–172. doi:10.1177/0044118X12456028
37. Boivin MJ, Bangirana P, Nakasujja N, et al. A Year-Long Caregiver Training Program Improves Cognition in Preschool Ugandan Children with HIV. *J Pediatr*. 2014;163(5):1–22. doi:10.1016/j.jpeds.2013.06.055.A
38. Dhamayanti M, Herlina M. Skrining Gangguan Kognitif dan Bahasa dengan Menggunakan Capute Scales (Cognitive Adaptive Test/Clinical Linguistic & Auditory

- Milestone Scale-Cat/Clams). *Sari Pediatr.* 2016;11(3):189. doi:10.14238/sp11.3.2009.189-98
39. Hermetet-lindsay KD. Contributions of Disease Severity , Psychosocial Factors , and Cognition to Behavioral Functioning in Youth Perinatally Exposed to HIV. 2015.
 40. Nagesh A, Amulya G, Goverdhan P, et al. Assessment of health related quality of life in children with epilepsy using Quality of Life in Childhood Epilepsy questionnaire (QOLCE-55) in tertiary care hospital. *J Basic Clin Pharm.* 2017;8(2):74–77.
 41. Momen AA, Abareian A, Malamiri RA. The evaluation of quality of life in children with Epilepsy . *Biomed Res.* 2019;30:1–5.
 42. Mannheimer SB, Matts J, Telzak E, Chesney M. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. *AIDS Care.* 2005;17(1):10–22. doi:10.1080/09540120412331305098
 43. Butler AM, Williams PL, Howland LC, Storm D, Hutton N. Impact of Disclosure of HIV Infection on Health-Related Quality of Life Among Children and Adolescents With HIV Infection. *Pediatrics.* 2009;123(3):935–943. doi:10.1542/peds.2008-1290
 44. Vreeman RC, Scanlon ML, Mwangi A, et al. A Cross-Sectional Study of Disclosure of HIV Status to Children and Adolescents in Western Kenya. *PLoS One.* 2014;9(1):1–10. doi:10.1371/journal.pone.0086616
 45. Martinez J, Chakraborty R. Psychosocial Support for Youth Living With HIV. *Am Acad Pediatr.* 2017;133(3):558–562. doi:10.1542/peds.2013-4061
 46. Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons : a prospective study in Southwest Ethiopia. *BMC Public Health.* 2008;8(265):1–9. doi:10.1186/1471-2458-8-265
 47. Ebissa G, Deyessa N, Biadgilign S. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia. *AIDS Care.* 2015;27(6):723–730. doi:10.1080/09540121.2014.997180
 48. Nugent J, Edmonds A, Lusima J, Thompson D. Predicting Mortality in HIV-infected Children Initiating Highly Active Antiretroviral Therapy in a Resource-deprived Setting. *Pediatr Infect Dis J.* 2014;33(11):1148–1155. doi:10.1097/INF.0000000000000454
 49. McDonald L, Rennie A, Tolmie J, Galloway P, McWilliam R. Investigation of global developmental delay. *Arch Dis Child.* 2006;91(8):701–705. doi:10.1136/ad.2005.078147
 50. Idris NS, Grobbee DE, Burgner D, et al. Cardiovascular manifestations of HIV infection

doi:10.1177/2047487314560086

51. Neto MG, Zwirter R, Brites C. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: Implications for clinical management. *Brazilian J Infect Dis.* 2013;17(6):691–700. doi:10.1016/j.bjid.2013.05.004
52. Mda S, van Raaij JMA, MacIntyre UE, de Villiers FPR, Kok FJ. Improved appetite after multi-micronutrient supplementation for six months in HIV-infected South African children. *Appetite.* 2010;54(1):150–155. doi:10.1016/j.appet.2009.09.021
53. Benki-Nugent S, Wamalwa D, Langat A, et al. Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: A prospective cohort study. *BMC Pediatr.* 2017;17(1):30–36. doi:10.1186/s12887-017-0776-1
54. Bruck I, Tahan TT, Rodrigues Da Cruz C, et al. Developmental milestones of vertically HIV infected and seroreverters children: Follow up of 83 children. *Arq Neuropsiquiatr.* 2001;59(3 B):691–695.
55. Buriti AKL, Oliveira SH dos S, Muniz LF. Hearing loss in children with HIV/AIDS. *Codas.* 2013;25(6):513–520. doi:10.1590/S2317-17822013.05000013
56. Hrapcak S, Kuper H, Bartlett P, et al. Hearing loss in HIV-infected children in Lilongwe, Malawi. *PLoS One.* 2016;11(8):1–14. doi:10.1371/journal.pone.0161421
57. Bednarek N, Motte J. Developmental delay and epilepsy. *Epileptic Disord.* 2006;8(SUPPL. 1):17–21.
58. Samia P, Petersen R, Walker KG, Eley B, Wilmschurst JM. Prevalence of seizures in children infected with human immunodeficiency virus. *J Child Neurol.* 2013;28(3):297–302. doi:10.1177/0883073812446161
59. Yadav SK, Gupta RK, Garg RK, et al. Altered structural brain changes and neurocognitive performance in pediatric HIV. *NeuroImage Clin.* 2017;14:316–322. doi:10.1016/j.nicl.2017.01.032
60. Phillips N, Amos T, Kuo C, et al. HIV-associated cognitive impairment in perinatally infected children: A meta-analysis. *Pediatrics.* 2016;138(5). doi:10.1542/peds.2016-0893
61. Nickels KC, Zaccariello MJ, Hamiwka LD, Wirrell EC. Cognitive and neurodevelopmental comorbidities in paediatric epilepsy. *Nat Rev Neurol.* 2016;12(8):465–476. doi:10.1038/nrneurol.2016.98
62. Lee GM, Gortmaker SL, McIntosh K, et al. Quality of life for children and adolescents:

- Impact of HIV infection and antiretroviral treatment. *Pediatrics*. 2006;117(2):273–283. doi:10.1542/peds.2005-0323
63. Gupta M, Nanda S, Kaushik JS. Quality of life in symptomatic HIV infected children. *Indian Pediatr*. 2013;50(12):1145–1147. doi:10.1007/s13312-013-0300-0
 64. Oberdorfer P, Louthrenoo O, Puthanakit T, Sirisanthana V, Sirisanthana T. Quality of Life Among HIV-Infected Children in Thailand. *J Int Assoc Physicians AIDS Care*. 2008;7(3):141–147.
 65. Shiferaw MB, Endalamaw D, Hussien M, et al. Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia. *BMC Infect Dis*. 2019;19(1):1–6. doi:10.1186/s12879-019-4058-4
 66. Humphrey JM, Genberg BL, Keter A, et al. Viral suppression among children and their caregivers living with HIV in western Kenya. *J Int AIDS Soc*. 2019;22(4):1–10. doi:10.1002/jia2.25272
 67. Shoko C, Chikobvu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. *BMC Infect Dis*. 2019;19(1):1–10. doi:10.1186/s12879-019-3781-1
 68. Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV care. *Curr Opin HIV AIDS*. 2017;12(2):123–128. doi:10.1097/COH.0000000000000348
 69. Shah I. Correlation of CD4 count, CD4% and HIV viral load with clinical manifestations of HIV in infected Indian children. *Ann Trop Paediatr*. 2006;26(2):115–119. doi:10.1179/146532806X107458
 70. Yin DE, Warshaw MG, Miller WC, et al. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. *Pediatrics*. 2014;134(4):e1104–e1116. doi:10.1542/peds.2014-0527
 71. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. *Curr HIV/AIDS Rep*. 2009;6(4):194–200. doi:10.1007/s11904-009-0026-8
 72. Mehta K, Ekstrand M, Heylen E, SAnjeeva G, Shet A. Adherence to antiretroviral therapy among children living with HIV in South India. *AIDS Behav*. 2016;20(5):1–14. doi:10.1016/j.physbeh.2017.03.040
 73. Biressaw S, Abegaz WE, Abebe M, Taye WA, Belay M. Adherence to Antiretroviral Therapy and associated factors among HIV infected children in Ethiopia: Unannounced home-based pill count versus caregivers' report. *BMC Pediatr*. 2013;13(1). doi:10.1186/1471-2431-13-132

74. Bankole KO, Bakare MO, Edet BE, et al. Psychological complications associated with HIV/AIDS infection among children in South-South Nigeria, sub-Saharan Africa. *Cogent Med.* 2017;4(1):1–16. doi:10.1080/2331205x.2017.1372869
75. Gutierrez-Colina AM, Smith AW, Mara CA, Modi AC. Adherence barriers in pediatric epilepsy: From toddlers to young adults. *Epilepsy Behav.* 2018;80:229–234. doi:10.1016/j.yebeh.2018.01.031
76. Lee YK, Ah YM, Choi YJ, Cho YS, Kim KJ, Lee JY. Antiepileptic drug adherence and persistence in children with epilepsy attending a large tertiary care children's hospital. *Epileptic Disord.* 2016;18(4):408–417. doi:10.1684/epd.2016.0871
77. Thea DM, Louis ME St., Atido U, et al. A Prospective Study of Diarrhea and HIV 1 Infection Among 429 Zairian Infants. *N Engl J Med.* 1993;329:987–994.
78. Guarino A, Bruzzese E, Marco G De, Buccigrossi V, De Marco G, Buccigrossi V. Management of gastrointestinal disorders in children with HIV infection. *Pediatr Drugs.* 2004;6(6):347–362. doi:10.2165/00148581-200406060-00003
79. Miller TL, Agostoni C, Duggan C, Guarino A, Manary M, Valasco CA. Gastrointestinal and Nutritional Complications of HIV Infection: Working Group for World Congress 2008. *J Pediatr Gastroenterol Nutr.* 2008;47(2):247–253. doi:10.1038/jid.2014.371
80. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre- and postantiretroviral treatment, North West Ethiopia. *J Blood Med.* 2017;8:99–105. doi:10.2147/JBM.S137067
81. Deressa T, Damtie D, Workineh M, Genetu M, Melku M. Anemia and thrombocytopenia in the cohort of HIV-infected adults in northwest Ethiopia: A facility-based cross-sectional study. *Electron J Int Fed Clin Chem Lab Med.* 2018;29(1):36–47.
82. Thulasi RR, Manimaran D, Hemanathan G, Afroz T, Sagar R. Hematological abnormalities in HIV infected individuals in correlation to CD4 counts and ART status. *Asian J Med Sci.* 2016;7(4):14–18. doi:10.3126/ajms.v7i4.14033